EFG Asset Management North America Corp. Has $5.53 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

EFG Asset Management North America Corp. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,375 shares of the company’s stock after selling 254 shares during the period. EFG Asset Management North America Corp.’s holdings in IDEXX Laboratories were worth $5,532,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the fourth quarter valued at $31,000. Kestra Investment Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $38,000. Finally, Crews Bank & Trust bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at $41,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.6 %

Shares of IDXX opened at $423.60 on Tuesday. The business’s fifty day moving average price is $437.38 and its two-hundred day moving average price is $444.44. The firm has a market capitalization of $34.34 billion, a price-to-earnings ratio of 39.70, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Morgan Stanley dropped their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.